USFDA26 Sept 2026, 12:30 pm
Zydus Lifesciences USA Office USFDA Inspection Concludes with Nil Observations
AI Summary
Zydus Lifesciences Ltd announced that the USFDA inspection of its pharmacovigilance and post-marketing surveillance system at its New Jersey, USA office has concluded. The inspection, which took place from September 22nd to September 25th, 2026, resulted in zero observations. This positive outcome signifies strong compliance with regulatory standards in a key market and is a significant development for the company's international operations.
Key Highlights
- USFDA inspection at Zydus' USA office completed.
- Inspection covered pharmacovigilance and post-marketing systems.
- The inspection concluded with zero observations.
- This indicates strong regulatory compliance in the USA.
Price Impact
More from ZYDUSLIFE